Sonidegib Suppresses Production of Inflammatory Mediators and Cell Migration in BV2 Microglial Cells and Mice Treated with Lipopolysaccharide via JNK and NF-κB Inhibition

Our structure-based virtual screening of the FDA-approved drug library has revealed that sonidegib, a smoothened antagonist clinically used to treat basal cell carcinoma, is a potential c-Jun N-terminal kinase 3 (JNK3) inhibitor. This study investigated the binding of sonidegib to JNK3 via (19)F NMR...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Ngoc Minh, Duong, Men Thi Hoai, Bui, Bich Phuong, Nguyen, Phuong Linh, Chen, Xiaozhen, Cho, Jungsook, Ahn, Hee-Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503982/
https://www.ncbi.nlm.nih.gov/pubmed/36142500
http://dx.doi.org/10.3390/ijms231810590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503982/
https://www.ncbi.nlm.nih.gov/pubmed/36142500
http://dx.doi.org/10.3390/ijms231810590

Ejemplares similares